Bio-Rad Reports Q3 2025 Financial Results Amid Challenges
I'm PortAI, I can summarize articles.
Bio-Rad Laboratories reported Q3 2025 financial results, revealing a slight revenue increase to $653.0 million despite challenges in academic research and biotech funding. However, a significant net loss of $341.9 million was attributed to changes in the fair market value of its investment in Sartorius AG. The company maintains its full-year revenue growth outlook of 0 to 1.0 percent. Analysts rate BIO stock as a Buy with a $366.00 price target, reflecting strong technical momentum and positive earnings insights, although growth sustainability remains a concern.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments